ARTICLE | Management Tracks
What Epstein, Viehbacher bring to the CEO roles at Seagen, Biogen
Chris Viehbacher could reprioritize Biogen via BD, while David Epstein could get Seagen’s launches on track
November 11, 2022 12:09 AM UTC
Two embattled major biopharmas have turned to the pharma old guard for new CEOs, hoping to leverage the execs’ respective track records in deal-making and commercial strategy to right their ships and reinstill confidence among investors.
Biogen Inc. (NASDAQ:BIIB) named Chris Viehbacher president and CEO, replacing Michel Vounatsos, while Seagen Inc. (NASDAQ:SGEN) named David Epstein CEO, taking over from interim CEO Roger Dansey...